Keyword: Eli Lilly

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.

While forthcoming migraine meds from Eli Lilly, Allergan and Biohaven do beat placebo, they're not much better than existing triptan drugs, ICER says.

Lilly and BI have taken the leading position with Jardiance, and now the partners are changing their 2011 alliance agreement to focus on the drug.

Cosentyx has been battling it out with Taltz in psoriatic arthritis. But Lilly’s drug has a big win under its belt that Novartis can't tout.

Lilly is facing off against new competition and dealing with lower pricing in the U.S., but key drug classes are continuing to expand, its CEO said.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.

While investors don't fancy megamergers, smaller deals in oncology could be the winning ticket, analysts have found.